J&J Opens Houston Incubator With 21 Startups, 12 Biopharma Firms
This article was originally published in Scrip
Johnson & Johnson Innovation LLC, the big pharma's early-stage company accelerator and partnership negotiator, opened its fifth US incubator to house and support startup firms with 21 tenants, including a dozen therapeutics developers, in the Houston, Texas facility.
You may also be interested in...
Scrip's second full day of meetings and events during the annual BIO International Convention delivered diverse insights about including patients in drug development, sharing risk with CROs, microbiome-targeting therapies, and the benefits of incubating early-stage technology.
Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?